- Annovis Bio announced **new biomarker data** from its Phase 2/3 AD study for **buntanetap**, demonstrating its ability to **attenuate inflammation and improve cellular health** in Alzheimer's patients.  **[1477845_500b065c636a488e85039dcf033ebd12_0]** 
- The analysis revealed buntanetap **reduced key inflammatory markers** (IL-5, IL-6, S100A12, IFN-γ, IGF1R) and **decreased NFL levels**, indicating improved cellular integrity and neuronal health.  **[1477845_500b065c636a488e85039dcf033ebd12_0]** 
- These positive responses were observed in **all patients with positive pTau217 plasma levels**, including those with mild and moderate stages of the disease, suggesting potential **disease-modifying effects**.  **[1477845_500b065c636a488e85039dcf033ebd12_0]** 
- Buntanetap is currently being evaluated in a **pivotal Phase 3 trial** in early AD (NCT06709014), which is actively enrolling and treating patients across the U.S..  **[1477845_500b065c636a488e85039dcf033ebd12_0]** 
- Full biomarker data will be presented at the **Clinical Trials on Alzheimer's Disease (CTAD) conference from December 1-4, 2025**.  **[1477845_500b065c636a488e85039dcf033ebd12_1]**

Annovis Bio (ANVS)